Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
Journal
British Journal of Cancer
Journal Volume
119
Journal Issue
2
Pages
153-159
Date Issued
2018
Author(s)
Mehra R.
Seiwert T.Y.
Gupta S.
Weiss J.
Gluck I.
Eder J.P.
Burtness B.
Tahara M.
Keam B.
Kang H.
Muro K.
Geva R.
Chung H.C.
Aurora-Garg D.
Ray A.
Pathiraja K.
Cheng J.
Chow L.Q.M.
Haddad R.
Abstract
Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC.
SDGs
Publisher
Nature Publishing Group
Type
journal article